This trial is active, not recruiting.

Condition stomach neoplasms
Sponsor Yonsei University
Start date May 2014
End date March 2015
Trial size 860 participants
Trial identifier NCT02136836, GSCH-STO13-01, Roche


The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective

Primary Outcomes

The proportion of HER2 overexpression in gastric cancer patients
time frame: 8 years

Secondary Outcomes

Gastric cancer specific survival according to HER2 expression in each stage
time frame: 5 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: 1. Histologically confirmed gastric adenocarcinoma 2. Patients were diagnosed during 2006-2013 3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion. Exclusion Criteria: - Patients with second primary cancer within 5 years

Additional Information

Principal investigator Jae Yong Cho, M.D.,Ph.D.
Trial information was received from ClinicalTrials.gov and was last updated in May 2014.
Information provided to ClinicalTrials.gov by Yonsei University.